Pharmacologic or genetic blockade of NK1-R curtails SP-driven chemotaxis, while the clinically approved antagonist aprepitant suppresses lamellipodia dynamics and reduces orthotopic tumour burden in vivo (49–51). Here, TACR1 is linked to neoplasm.